CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
5.70
1.72%
Market Trading Hours* (UTC) Opens on Tuesday at 01:30

Mon - Fri: 01:30 - 04:00 05:00 - 08:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.35
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022703 %
Charges from full value of position ($-4.31)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022703%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.000785 %
Charges from full value of position ($0.15)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.000785%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency HKD
Margin 5%
Stock exchange Hong Kong
Commission on trade 0%

*Information provided by Capital.com

3SBio Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 5.8
Open* 5.8
1-Year Change* -27.04%
Day's Range* 5.65 - 5.8
52 wk Range 6.05-9.10
Average Volume (10 days) 8.98M
Average Volume (3 months) 167.29M
Market Cap 15.56B
P/E Ratio 7.65
Shares Outstanding 2.44B
Revenue 8.21B
EPS 0.83
Dividend (Yield %) 1.5674
Beta 0.90
Next Earnings Date Mar 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 15, 2024 5.75 0.00 0.00% 5.75 5.80 5.70
Apr 12, 2024 5.80 -0.05 -0.85% 5.85 5.90 5.75
Apr 11, 2024 5.85 0.05 0.86% 5.80 5.90 5.75
Apr 10, 2024 5.90 -0.20 -3.28% 6.10 6.15 5.85
Apr 9, 2024 6.15 0.30 5.13% 5.85 6.20 5.85
Apr 8, 2024 5.90 0.05 0.85% 5.85 5.95 5.75
Apr 5, 2024 5.85 -0.10 -1.68% 5.95 5.95 5.70
Apr 3, 2024 5.95 0.05 0.85% 5.90 6.00 5.85
Apr 2, 2024 5.90 0.10 1.72% 5.80 6.00 5.70
Mar 28, 2024 5.85 0.20 3.54% 5.65 5.90 5.50
Mar 27, 2024 5.60 -0.15 -2.61% 5.75 5.75 5.55
Mar 26, 2024 5.75 -0.10 -1.71% 5.85 5.90 5.75
Mar 25, 2024 5.85 0.10 1.74% 5.75 6.00 5.70
Mar 22, 2024 5.80 0.50 9.43% 5.30 5.90 5.30
Mar 21, 2024 5.25 0.05 0.96% 5.20 5.35 5.10
Mar 20, 2024 5.35 0.15 2.88% 5.20 5.40 5.20
Mar 19, 2024 5.25 0.00 0.00% 5.25 5.25 5.15
Mar 18, 2024 5.25 0.20 3.96% 5.05 5.35 5.05
Mar 15, 2024 5.05 -0.10 -1.94% 5.15 5.20 5.05
Mar 14, 2024 5.15 -0.05 -0.96% 5.20 5.30 5.10

3SBio Inc. Events

Time (UTC) Country Event
Wednesday, June 19, 2024

Time (UTC)

02:00

Country

CN

Event

3SBio Inc Annual Shareholders Meeting
3SBio Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 22, 2024

Time (UTC)

10:59

Country

CN

Event

Half Year 2024 3SBio Inc Earnings Release
Half Year 2024 3SBio Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 6859.43 6382.01 5587.64 5318.09 4583.87
Revenue 6859.43 6382.01 5587.64 5318.09 4583.87
Cost of Revenue, Total 1187.53 1106.29 1062.91 925.347 877.255
Gross Profit 5671.9 5275.72 4524.73 4392.74 3706.61
Total Operating Expense 4450.7 4409.62 4497.05 3974.57 2941.73
Selling/General/Admin. Expenses, Total 3034.56 2803.02 2480 2668.55 2075.93
Research & Development 693.172 753.872 590.343 526.565 362.706
Interest Expense (Income) - Net Operating -663.277 -237.673 165.524 -131.48 -348.558
Unusual Expense (Income) 245.558 27.409 171.668 3.367 10.054
Other Operating Expenses, Total -46.84 -43.3 26.599 -17.779 -35.66
Operating Income 2408.73 1972.39 1090.59 1343.52 1642.14
Interest Income (Expense), Net Non-Operating -134.7 -103.626 -111.459 -120.507 -146.627
Net Income Before Taxes 2274.03 1868.77 979.129 1223.01 1495.51
Net Income After Taxes 1908.02 1627.57 771.106 980.228 1277.25
Minority Interest 6.868 23.674 64.685 -6.511 -0.079
Net Income Before Extra. Items 1914.89 1651.25 835.791 973.717 1277.17
Net Income 1914.89 1651.25 835.791 973.717 1277.17
Income Available to Common Excl. Extra. Items 1914.89 1651.25 835.791 973.717 1277.17
Income Available to Common Incl. Extra. Items 1914.89 1651.25 835.791 973.717 1277.17
Diluted Net Income 1968.25 1651.25 835.791 973.717 1349.94
Diluted Weighted Average Shares 2648.21 2770.12 2750.82 2537.74 2754.04
Diluted EPS Excluding Extraordinary Items 0.74324 0.59609 0.30383 0.38369 0.49017
Dividends per Share - Common Stock Primary Issue 0.16296 0
Diluted Normalized EPS 0.82104 0.60471 0.35298 0.38476 0.49329
Dilution Adjustment 53.365 72.773
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 3783.83 3768.07 3094.46 3274.87 3107.14
Revenue 3783.83 3768.07 3094.46 3274.87 3107.14
Cost of Revenue, Total 582.279 661.15 529.285 586.295 519.991
Gross Profit 3201.55 3106.92 2565.18 2688.58 2587.14
Total Operating Expense 2490.33 2511 1928.19 2377.01 2032.6
Selling/General/Admin. Expenses, Total 1581.17 1648.85 1370.82 1488.22 1314.8
Research & Development 306.593 399.06 294.337 409.021 344.851
Interest Expense (Income) - Net Operating 85.574 -350.369 -312.333 -130.138 -107.535
Unusual Expense (Income) -45.701 177.284 68.274 43.495 -16.086
Other Operating Expenses, Total -19.592 -24.973 -22.194 -19.88 -23.42
Operating Income 1293.51 1257.07 1166.27 897.86 1074.53
Interest Income (Expense), Net Non-Operating -99.439 -87.737 -49.266 -54.947 -48.679
Net Income Before Taxes 1194.07 1169.33 1117.01 842.913 1025.85
Net Income After Taxes 986.467 967.36 953.034 736.548 891.025
Minority Interest -5.89 -6.991 13.859 15.791 7.883
Net Income Before Extra. Items 980.577 960.369 966.893 752.339 898.908
Net Income 980.577 960.369 966.893 752.339 898.908
Income Available to Common Excl. Extra. Items 980.577 960.369 966.893 752.339 898.908
Income Available to Common Incl. Extra. Items 980.577 960.369 966.893 752.339 898.908
Diluted Net Income 956.854 985.162 995.465 721.656 929.591
Diluted Weighted Average Shares 2443.51 2622.76 2673.66 2773.74 2766.5
Diluted EPS Excluding Extraordinary Items 0.39159 0.37562 0.37232 0.26017 0.33602
Diluted Normalized EPS 0.37614 0.43154 0.39411 0.27388 0.33097
Dilution Adjustment -23.723 24.793 28.572 -30.683 30.683
Dividends per Share - Common Stock Primary Issue 0 0 0.16296 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 9760.92 7790.7 6679.91 4596.18 4437.53
Cash and Short Term Investments 7010.51 4768.1 4363.7 2555.01 1860.74
Cash & Equivalents 2868.08 3090.83 2082.85 1792.6
Short Term Investments 4861.05 1900.02 1272.86 472.163 68.132
Total Receivables, Net 1623.44 1866.31 1534.66 1464.67 2141.37
Accounts Receivable - Trade, Net 1217.5 1288.83 860.001 930.78 1347.03
Total Inventory 712.164 690.523 619.508 528.473 384.609
Prepaid Expenses 68.319 281.174 36.222 25.951 36.511
Other Current Assets, Total 346.487 184.592 125.823 22.073 14.305
Total Assets 21988.7 19212.6 17678.2 14809.3 13839.7
Property/Plant/Equipment, Total - Net 4707.85 3828.25 2979.39 2324.73 1791.96
Property/Plant/Equipment, Total - Gross 6109.49 5086.33 4075.5 3243.17 2532.97
Accumulated Depreciation, Total -1401.64 -1258.08 -1096.11 -918.436 -741.009
Goodwill, Net 4140.06 3843.88 3918.92 4145.9 4089.06
Intangibles, Net 1578.31 1849.16 1898.48 2165.14 2298.74
Long Term Investments 1380.01 1321.27 1654.38 1277.87 701.596
Note Receivable - Long Term 0 2.2 6.555 28.758
Other Long Term Assets, Total 421.551 579.31 544.91 292.933 492.008
Total Current Liabilities 1793.93 1419.99 1450.92 1611.73 1655.54
Accounts Payable 249.495 230.407 203.286 149.763 112.915
Accrued Expenses 742.734 643.396 496.483 636.449 618.052
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 375.493 160.753 367.158 489.424 570.328
Other Current Liabilities, Total 426.209 385.433 383.994 336.093 354.246
Total Liabilities 9026.03 6985.12 6988.88 5184.27 5225.22
Total Long Term Debt 4093.07 2468.13 2546.96 2322 2724.34
Long Term Debt 4065.48 2435.75 2514.74 2318.04 2724.34
Deferred Income Tax 279.865 264.468 272.242 268.077 270.761
Minority Interest 2437.78 2430.35 2404.02 734.278 292.937
Other Liabilities, Total 421.388 402.195 314.736 248.181 281.64
Total Equity 12962.7 12227.5 10689.3 9625.04 8614.43
Common Stock 0.149 0.155 0.155 0.155 0.156
Additional Paid-In Capital 4025.61 4490.38 4645.02 4553.41 4585.73
Retained Earnings (Accumulated Deficit) 9032.18 7534.44 5704.9 4868.09 3894.37
Unrealized Gain (Loss) -35.502 98.378 197.089 1.052 0.157
Other Equity, Total 175.876 104.103 142.15 202.329 174.597
Total Liabilities & Shareholders’ Equity 21988.7 19212.6 17678.2 14809.3 13839.7
Total Common Shares Outstanding 2398.51 2522.36 2543.6 2535.05 2543.71
Treasury Stock - Common -235.641 0 -40.586
Capital Lease Obligations 27.587 32.38 32.219 3.964
Cash 2149.46
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 10251.3 9760.92 8854.75 7790.7 7401.7
Cash and Short Term Investments 6672.54 7010.51 6232.4 4768.1 4801.58
Cash & Equivalents 2868.08 2919.68
Short Term Investments 4601.75 4861.05 3343.46 1900.02 1881.9
Total Receivables, Net 1337.81 1310.06 1166.78 1378.76 1224.1
Accounts Receivable - Trade, Net 1258.87 1217.5 1147.17 1288.83 1153.44
Total Inventory 740.024 712.164 766.78 690.523 681.498
Prepaid Expenses 1306.33 518.965 506.108 768.726 582.659
Other Current Assets, Total 194.599 209.218 182.688 184.592 111.864
Total Assets 23169.9 21988.7 20521.3 19212.6 18541.2
Property/Plant/Equipment, Total - Net 4675 4466.31 4005.62 3828.25 3435.99
Goodwill, Net 4271.43 4140.06 4012.72 3843.88 3886.33
Intangibles, Net 1568.94 1578.31 1826.85 1849.16 1851.26
Long Term Investments 1740.58 1380.01 1265.66 1321.27 1428.62
Note Receivable - Long Term 0 0
Other Long Term Assets, Total 662.647 663.089 555.674 579.31 537.349
Total Current Liabilities 3559.64 1793.93 1872.91 1419.99 1334.97
Accounts Payable 273.875 249.495 263.876 230.407 214.946
Accrued Expenses 683.11 742.734 583.823 643.396 568.949
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2009.54 375.493 261.642 160.753 159.426
Other Current Liabilities, Total 593.117 426.209 763.566 385.433 391.645
Total Liabilities 9649.16 9026.03 8518.08 6985.12 6808.73
Total Long Term Debt 2961.92 4093.07 3581.29 2468.13 2485.98
Long Term Debt 2939.22 4065.48 3551.21 2435.75 2452.38
Capital Lease Obligations 22.706 27.587 30.081 32.38 33.601
Deferred Income Tax 259.136 279.865 259.958 264.468 266.194
Minority Interest 2443.67 2437.78 2418.78 2430.35 2396.14
Other Liabilities, Total 424.795 421.388 385.146 402.195 325.455
Total Equity 13520.8 12962.7 12003.2 12227.5 11732.5
Common Stock 0.149 0.149 0.149 0.155 0.156
Additional Paid-In Capital 3813.54 4025.61 4025.25 4490.38 4665.96
Retained Earnings (Accumulated Deficit) 9965.85 9032.18 8071.81 7534.44 6777.63
Treasury Stock - Common -235.641 -235.641 -235.641
Unrealized Gain (Loss) -106.558 -35.502 -13.504 98.378 162.96
Other Equity, Total 83.419 175.876 155.136 104.103 125.803
Total Liabilities & Shareholders’ Equity 23169.9 21988.7 20521.3 19212.6 18541.2
Total Common Shares Outstanding 2438.92 2398.51 2438.85 2522.36 2549.25
Cash 2070.79 2149.46 2888.94
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 2274.03 1868.77 979.129 1223.01 1495.51
Cash From Operating Activities 2180.28 1578.34 1344.56 1887.38 1150.25
Cash From Operating Activities 203.787 205.65 204.383 198.9 165.248
Amortization 162.319 123.352 156.554 135.068 148.016
Non-Cash Items -183.536 -0.169 560.395 341.251 -152.08
Cash Taxes Paid 346.37 286.822 254.046 355.329 263.338
Cash Interest Paid 45.563 6.262 196.078 38.236 66.968
Changes in Working Capital -276.325 -619.254 -555.9 -10.848 -506.444
Cash From Investing Activities -3721.99 -1286.52 -1869.48 -1133.72 -405.912
Capital Expenditures -973.734 -1145.77 -981.473 -486.253 -462.396
Other Investing Cash Flow Items, Total -2748.25 -140.743 -888.008 -647.464 56.484
Cash From Financing Activities 714.912 -481.119 1550.69 -454.4 -1389.68
Financing Cash Flow Items -25.891 36.413 1533.48 108.099 -9.427
Issuance (Retirement) of Stock, Net -475.511 -408.764 -10.12 -31.046 -40.586
Issuance (Retirement) of Debt, Net 1633.45 -108.768 27.326 -515.114 -1188.85
Foreign Exchange Effects 109.004 -33.468 -17.778 -9.025 39.323
Net Change in Cash -717.791 -222.758 1007.99 290.242 -606.016
Total Cash Dividends Paid -417.14 0 -16.339 -150.813
Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
Net income/Starting Line 2274.03 1104.7 1868.77 1025.85 979.129
Cash From Operating Activities 2180.28 1073.4 1578.34 811.497 1344.56
Cash From Operating Activities 203.787 101.43 205.65 99.91 204.383
Amortization 162.319 77.666 123.352 59.811 156.554
Non-Cash Items -183.536 -131.621 -0.169 -79.445 560.395
Cash Taxes Paid 346.37 168.859 286.822 123.958 254.046
Cash Interest Paid 45.563 7.36 6.262 1.552 196.078
Changes in Working Capital -276.325 -78.777 -619.254 -294.632 -555.9
Cash From Investing Activities -3721.99 -1810.36 -1286.52 -765.999 -1869.48
Capital Expenditures -973.734 -322.821 -1145.77 -530.541 -981.473
Other Investing Cash Flow Items, Total -2748.25 -1487.54 -140.743 -235.458 -888.008
Cash From Financing Activities 714.912 774.017 -481.119 -202.947 1550.69
Financing Cash Flow Items -25.891 4.145 36.413 -0.987 1533.48
Total Cash Dividends Paid -417.14 0
Issuance (Retirement) of Stock, Net -475.511 -475.68 -408.764 4.133 -10.12
Issuance (Retirement) of Debt, Net 1633.45 1245.55 -108.768 -206.093 27.326
Foreign Exchange Effects 109.004 24.06 -33.468 -13.703 -17.778
Net Change in Cash -717.791 61.114 -222.758 -171.152 1007.99

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

3SBio Company profile

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. The company's primary products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; Yisaipu, a tumour necrosis factor for treating rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and EPIAO, a recombinant human erythropoietin for the treatment of anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and reduction of allogeneic blood transfusion in surgery patients. Its primary products also comprise SEPO, a recombinant human erythropoietin for anemia associated with CKD and chemotherapy; Byetta/Bydureon, an exenatide injection to improve glycemic control in adults with type-2 diabetes mellitus; and Qiming Keli for retinopathy caused by type-2 diabetes. In addition, the company offers Ruisiyi to treat advanced breast cancer; Wanwei for treating vomiting caused by cytotoxic chemotherapy; and Intefen to treat lymphatic or hematopoietic malignancies and viral infections. Further, it provides Inleusin for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; Etanercept for moderate to severe rheumatoid arthritis and plaque psoriasis, and active ankylosing spondylitis; and Sparin for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. Additionally, the company offers Mandi for male-pattern alopecia and alopecia areata; Aiyishu for iron-deficiency anemia; Disu to prevent and treat chronic bronchitis, colds, and asthma; Jiannipai to prevent acute rejection after renal transplantation; and Humulin for diabetes, as well as contract development and manufacturing, trading, project management and consultation, and technology services. The company markets its products through in-house sales and marketing team, as well as distributors and third-party promoters. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, the People's Republic of China.
Industry: Biopharmaceuticals

瀋陽經濟技術開發區十號路1甲3號
SHENYANG
LIAONING
CN

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

XRP/USD

0.50 Price
+1.420% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,367.50 Price
+0.660% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0107%
Overnight fee time 21:00 (UTC)
Spread 0.50

BTC/USD

64,054.90 Price
+0.480% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

ETH/USD

3,109.08 Price
+1.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading